Brief: ADC Therapeutics Announces Plan To Discontinue The Phase 2 Lotis-9 Clinical Trial Of Zynlonta, Rituximab

ADC Therapeutics SA

20/07/2023 21:39

July 20 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * ADC THERAPEUTICS ANNOUNCES PLAN TO DISCONTINUE THE PHASE 2
LOTIS-9 CLINICAL TRIAL OF ZYNLONTA® (LONCASTUXIMAB
TESIRINE-LPYL) AND RITUXIMAB IN UNFIT OR FRAIL PREVIOUSLY
UNTREATED DLBCL PATIENTS
    * ADC THERAPEUTICS SA - U.S. FOOD AND DRUG ADMINISTRATION
(FDA)
PLACED A PARTIAL CLINICAL HOLD ON TRIAL FOR NEW PATIENT
ENROLLMENT
    * ADC THERAPEUTICS SA - FDA WILL ALLOW PATIENTS ALREADY ON
THERAPY
WHO ARE DERIVING CLINICAL BENEFIT TO REMAIN ON THERAPY AFTER
BEING RECONSENTED
    * ADC THERAPEUTICS SA - FOLLOWING TREATMENT OF ANY
RECONSENTING
PATIENTS, COMPANY WILL CONDUCT NECESSARY STEPS TO CONCLUDE TRIAL
    * ADC THERAPEUTICS SA - DOES NOT PLAN TO CONTINUE STUDYING
THIS
REGIMEN IN UNFIT OR FRAIL PREVIOUSLY UNTREATED DLBCL PATIENT
POPULATION

Source text for Eikon:  ID:nGNX7HfKrm 
Further company coverage:  ADCT.N 

 ((reuters.briefs@thomsonreuters.com;))